Scholarlink

<p>Uterine leiomyosarcoma (ULMS) is a rare gynecological malignancy with a high recurrence rate and poor prognosis. No standard treatment exists for recurrent cases. Recent studies indicate that homozygous BRCA2 deletion may serve as a therapeutic target in non-BRCA-associated malignancies, including ULMS. Here, we report a 49-year-old woman with recurrent BRCA2-deficient ULMS who responded to carboplatin monotherapy. Although PARP inhibitors have been utilized in BRCA-mutated ULMS, this case underscores the potential efficacy of platinum-based chemotherapy as an alternative treatment strategy. Furthermore, a therapeutic approach integrating platinum-based chemotherapy followed by PARP inhibitor maintenance, similar to that employed in platinum-sensitive ovarian cancer, warrants further investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Carboplatin monotherapy in recurrent uterine leiomyosarcoma with homozygous BRCA2 deletion: a case report

  • 期刊论文

  • 发表日期：

    2025年11月21日

查看全文
  • Takafumi Ujihira,
  • Yukiko Namba,
  • Sumire Ishii,
  • Toshiyuki Okumura,
  • Koyo Yoshida,
  • Shintaro Makino

摘要

Uterine leiomyosarcoma (ULMS) is a rare gynecological malignancy with a high recurrence rate and poor prognosis. No standard treatment exists for recurrent cases. Recent studies indicate that homozygous BRCA2 deletion may serve as a therapeutic target in non-BRCA-associated malignancies, including ULMS. Here, we report a 49-year-old woman with recurrent BRCA2-deficient ULMS who responded to carboplatin monotherapy. Although PARP inhibitors have been utilized in BRCA-mutated ULMS, this case underscores the potential efficacy of platinum-based chemotherapy as an alternative treatment strategy. Furthermore, a therapeutic approach integrating platinum-based chemotherapy followed by PARP inhibitor maintenance, similar to that employed in platinum-sensitive ovarian cancer, warrants further investigation.